Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose
Launched by MEDICIS GLOBAL SERVICE CORPORATION · Jan 14, 2009
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
This is a split-face design. All 60 subjects receive Perlane on one side of their face, and Perlane-L on the other. Subjects and the investigator is blinded to which side of face receives which product. These are one time injections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Same Wrinkle Severity Rating Scale score at both Nasolabial Folds (either both Moderate \[3\] or both Severe \[4\])
- Exclusion Criteria:
- • Active or chronic skin disease, inflammation or related conditions, near or on the Nasolabial Folds
- • Subjects who had undergone procedures based on active dermal response (e.g., laser or chemical peeling procedures) within 6 months prior to study entry
- • Use of any facial tissue augmenting therapy with non-permanent filler or aesthetic facial surgical therapy within 9 months prior to study entry
- • Permanent implant placed in the Nasolabial Fold area
About Medicis Global Service Corporation
Medicis Global Service Corporation is a distinguished clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong commitment to improving patient outcomes, the organization specializes in conducting rigorous clinical trials across various therapeutic areas. Leveraging a team of experienced professionals and state-of-the-art methodologies, Medicis Global Service Corporation ensures the highest standards of safety, efficacy, and ethical practice in all its studies. By fostering collaboration with healthcare providers and regulatory bodies, the company aims to bring groundbreaking therapies to market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Coral Gables, Florida, United States
Hunt Valley, Maryland, United States
Mount Cisco, New York, United States
Patients applied
Trial Officials
Mary Sanstead
Study Chair
Medicis Global Pharmaceutical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials